Recruiting

GLP-1 Medications

Sponsor:

Penn State University

Code:

NCT06843512

Conditions

Weight Loss

Food Selection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GLP-1 Medication Initiation

Study Details

Brief summary:

In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.

Conditions

Weight Loss

Food Selection

Study ID

NCT06843512

Start date

Jul 15, 2025

Status verified date

Sep, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults (18+) with overweight or obesity (BMI >25 kg/m2)
  • Not currently taking an incretin-based medication at baseline
  • Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
  • Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
  • Fluent in English

Exclusion Criteria:

  • Adults (18+) without overweight or obesity
  • <18 years of age at time of testing
  • Adults not taking a GLP-1 Medication
  • Adults taking a compound GLP-1
  • Adults on GLP-1 medication for longer than 2 weeks at baseline
  • Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
  • Not fluent in English

Study Design

Enrollment

25 participants

Anticipated

Interventions and Outcome Measures

Interventions

GLP-1 Medication Initiation

One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.

Primary outcome measure

  • Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months [ Time Frame: Baseline and 3 months ]
  • Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 Months [ Time Frame: Baseline and 3 months ]
  • Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 Months [ Time Frame: Baseline and 3 months ]
  • Change from Baseline in Variety of Food Selected in the VR Buffet at 3 Months [ Time Frame: Baseline and 3 months ]

Central Contacts and Locations

Central contacts

Christina M Blackmon

425-499-8049cmb8633@psu.edu

Locations

Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University

Recruiting

State College, Pennsylvania, United States, 16802

Contacts

Christina M Blackmon

425-499-8049cmb8633@psu.edu

More Information

Sponsor

Penn State University

Last update posted

Sep 10, 2025

Last verified

Sep, 2025

Keywords

  • GLP-1
  • Weight Loss
  • Virtual Reality
  • Food behavior

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Penn State University on 2025-09-10.